Lyra Therapeutics (LYRA) Total Non-Current Liabilities (2019 - 2025)

Lyra Therapeutics (LYRA) has reported Total Non-Current Liabilities for 7 consecutive years, with $48.0 million the latest figure, recorded in Q3 2025.

• Total Non-Current Liabilities for Q3 2025 came in at $48.0 million, down 17.37% year-over-year; the trailing twelve-month figure through Sep 2025 was $48.0 million (down 17.37% YoY), and the FY2024 annual result was $54.8 million, up 2.96% from the prior year.
• Total Non-Current Liabilities for Q3 2025 stood at $48.0 million, down from $51.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $64.0 million in Q1 2024, with the low at $5.4 million in Q1 2021.
• A 5-year average of $38.3 million and a median of $36.3 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities fell 26.99% in 2021 and soared 348.9% in 2022, its largest moves.
• Lyra Therapeutics' Total Non-Current Liabilities stood at $20.6 million in 2021, then surged by 42.15% to $29.2 million in 2022, then jumped by 82.04% to $53.2 million in 2023, then climbed by 2.96% to $54.8 million in 2024, then retreated by 12.26% to $48.0 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $48.0 million (Q3 2025), $51.0 million (Q2 2025), and $52.4 million (Q1 2025), per Business Quant data.